Tariffs on Indian generics will hike US healthcare costs: USISPF
UPSC / SSC current affairs note · Economy
Why in news
USISPF President Mukesh Aghi warned that proposed tariffs on Indian generic medicines will increase US healthcare costs. India supplies 40% of US generics, many used in government programs like Medicare, so tariffs would raise costs for the US government itself.
Background
The US has been considering tariffs on Indian pharmaceutical imports as part of trade policy. India is a major supplier of generic drugs to the US, accounting for a significant share of prescriptions.
Key facts
India supplies 40% of generic medicines used in the United States.
Many Indian generics are used in US government programs like Medicare.
Proposed tariffs on Indian generics would increase healthcare costs for the US government.
USISPF (US-India Strategic Partnership Forum) is a business advocacy group.
Mukesh Aghi is the President of USISPF.
Prelims pointers
- USISPF: US-India Strategic Partnership Forum
- Medicare: US federal health insurance program for seniors
- Generic medicines: off-patent drugs, cheaper than branded versions
Mains angles
- Impact of trade tariffs on healthcare costs and access
- India-US trade relations and pharmaceutical sector
- Role of generic drugs in global health systems